Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children

Myocardial Injury and Bacterial Pneumonia Contribute to the Pathogenesis of Fatal Influenza B Virus Infection

(2012) Christopher D. Paddock et al.   JOURNAL OF INFECTIOUS DISEASES

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine

(2012) Carrie Reed et al.   VACCINE

Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial

(2012) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010

(2011) et al.   Influenza and Other Respiratory Viruses

Clinical manifestations and socio-economic impact of influenza among healthy children in the community

(2011) Susanna Esposito et al.   JOURNAL OF INFECTION

Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata

(2011) Danuta M. Skowronski et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months

(2011) D. M. Skowronski et al.   PEDIATRICS

Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children

(2011) Vladimir Gilca et al.   VACCINE

The need for quadrivalent vaccine against seasonal influenza

(2010) Robert B. Belshe   VACCINE

Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity

(2009) Robert B. Belshe et al.   VACCINE